2021 – Satellos

SATELLOS Announces 2021 Year End Financial Results and Operational Highlights

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,

Jessica Richmond2022-05-02T22:18:01+00:00May 2nd, 2022|2021, 2022, Press Releases|

SATELLOS BIOSCIENCE INC. ANNOUNCES SCIENTIFIC RESEARCH AGREEMENT WITH UNIVERSITÉ DE SHERBROOKE TO STUDY RARE MUSCULAR

Jessica Richmond2022-01-28T16:35:24+00:00December 16th, 2021|2021, Press Releases|

SATELLOS BIOSCIENCE ANNOUNCES NEW BOARD APPOINTMENTS Satellos welcomes new board members to strengthen its pharmaceutical

Jessica Richmond2022-01-28T16:36:29+00:00December 6th, 2021|2021, Press Releases|

SATELLOS BIOSCIENCE REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Satellos positioned to pursue

Jessica Richmond2022-01-28T16:37:16+00:00November 29th, 2021|2021, Press Releases|

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,

ico_admin2022-01-28T16:38:36+00:00October 26th, 2021|2021, Press Releases|

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES Toronto,

ico_admin2022-01-28T16:39:21+00:00September 17th, 2021|2021, Press Releases|

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,

ico_admin2022-01-28T16:40:00+00:00September 13th, 2021|2021, Press Releases|

Toronto, Ontario -- (August 30, 2021) Satellos Therapeutics Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics

ico_admin2022-01-28T16:41:20+00:00August 30th, 2021|2021, Press Releases|

SATELLOS BIOSCIENCE Announces High Resolution Crystal Structure of Duchenne Drug Target TORONTO, ONTARIO –August 26,

ico_admin2022-01-28T16:41:54+00:00August 26th, 2021|2021, Press Releases|

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,

ico_admin2022-01-28T16:42:11+00:00August 25th, 2021|2021, Press Releases|